Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of the supply of (a) Lisdexamfetamine and (b) Bupropion Hydrochloride.

The Department is aware of intermittent supply disruptions affecting Elvanse (lisdexamfetamine) capsules. We continue to work with the respective manufacturer to ensure continuous supply is resumed quickly. However, we can confirm that Elvanse 20mg, 40mg and 60mg capsules are currently in stock and pharmacies should be able to obtain stock via normal wholesaler routes.

We are also aware of a shortage with Bupropion. The resupply date of this product is still to be confirmed. We have issued comprehensive management guidance to healthcare professionals on this shortage in December 2022. Guidance advises on the management of patients who require this medication for both licensed and off-label indications. Clinicians can advise patients on suitable alternative products, and other management options that can be considered. This includes unlicensed bupropion 150mg modified release tablets which have been sourced.